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Background. It is unclear if CD4 cell counts at HIV diagnosis have improved over a 10-year period of expanded HIV testing in
the USA. Methods. We studied HOPS participants diagnosed with HIV infection ≤6 months prior to entry into care during 2000–
2009. We assessed the correlates of CD4 count <200 cells/mm3 at HIV diagnosis (late HIV diagnosis) by logistic regression.Results.
Of 1,203 eligible patients, 936 (78%) had a CD4 count within 3 months after HIV diagnosis. Median CD4 count at HIV diagnosis
was 299 cells/mm3 and did not signiﬁcantly improve over time (P = 0.13). Comparing periods 2000-2001 versus 2008-2009,
respectively, 39% and 35% of patients had a late HIV diagnosis (P = 0.34). Independent correlates of late HIV diagnosis were
having an HIV risk other than being MSM, age ≥35 years at diagnosis, and being of nonwhite race/ethnicity. Conclusions.T h e r e
is need for routine universal HIV testing to reduce the frequency of late HIV diagnosis and increase opportunity for patient- and
potentially population-level beneﬁts associated with early antiretroviral treatment.
1.Introduction
Recent HIV surveillance data suggest that approximately
33% of HIV-infected persons in the United States present
for HIV testing late and have AIDS (CD4+ cell count
<200cells/mL or an AIDS-deﬁning illness) within one
year after HIV diagnosis [1, 2]. Patients are less likely to
experience the full beneﬁts of highly active combination
antiretroviral (cART) therapy if they enter HIV care and
initiate treatment at a CD4 count <350cells/mm3 [3, 4]; the
clinical cost is even more profound when the CD4 count is
<200cells/mm3 or the patient has already developed clinical
AIDS [5–8]. In addition, persons who remain unaware of
their HIV-positive status (estimated 21% to 25% of infected
persons in the USA in recent years) [9, 10] may not only
missthebeneﬁtsofearliercARTtreatment,butarealsomore
likely to remain chronically viremic and are thereby more
likely to transmit HIV to their sexual and needle-sharing
partners [9].
The CDC has been promoting strategies to encourage
morewidespreadHIVscreeningtodiagnoseinfectedpersons
earlier in the course of their illness, including by releasing
in 2006 the guidelines for implementing routine universal
opt-out testing in healthcare settings [11]. Yet, the latest HIV
surveillancedata[1,2]andepidemiologicstudiesinmultiple
US populations indicate that the proportion of persons who
are diagnosed late in the course of HIV infection [2, 12, 13]
or present late for HIV care [14, 15] remains unacceptably
high.Stableorworseningtrendsintheproportionofpatients
HIVdiagnosedwithlowCD4countshavealsobeenobserved
internationally [16–18]. However, encouraging trends have
been seen in select US jurisdictions which have dramatically
expanded their HIV testing programs [19, 20]. With the
recent shift in antiretroviral treatment guidelines toward
earlier therapy initiation to beneﬁt patients’ health [21]a n d
thegrowinginterestinHIV“testandtreat”and“testandlink
tocare-plus”strategiestolimitthespreadoftheUSepidemic
[22], it is important to understand the burden of late HIV2 AIDS Research and Treatment
diagnosis among contemporary US patients as it aﬀects the
likelihood of success of these interventions.
We studied participants in the HIV Outpatient Study
(HOPS) who were recently diagnosed with HIV infection
to examine the trends in median CD4 count at diagnosis
and the proportion of patients diagnosed with CD4 count
<200cells/mm3 (also termed “late HIV diagnosis”) during
2000–2009.
2. Methods
2.1. The HIV Outpatient Study (HOPS). The HOPS is
an ongoing, open prospective observational cohort study
that has continuously recruited and followed HIV-infected
patients since 1993. Since the HOPS’ inception, the study
siteshaveincluded10clinics(6university,2public,2private)
in eight US cities and provided care for about 3,000 HIV-
infected patients per year. Over 9,600 HOPS patients have
been seen during more than 390,000 clinical encounters. The
study protocol is approved and renewed annually by each
participating institution’s ethical review board. All study
participants provide written, informed consent.
HOPS clinicians have extensive experience treating HIV-
infected patients. Information is abstracted from outpatient
charts at each visit, entered electronically by trained staﬀ,
compiled centrally, and reviewed and edited before being
analyzed. Abstracted information includes demographic
characteristics and risk factors for HIV infection; diag-
noses; symptoms; prescribed medications, including dose
and duration; laboratory values, including CD4 counts and
plasma HIV viral loads; causes of mortality and hospitaliza-
tions.
2.2. Study Population. We analyzed data from HOPS partic-
ipants using the dataset updated as of March 30, 2011. The
10 clinics included in the analyses were located in Tampa,
FL (2 sites); Washington, DC; Denver, CO (2 sites); Chicago,
IL (2 sites); Stony Brook, NY; Oakland, CA; Walnut Creek,
CA, and Philadelphia, PA. We limited analyses to patients
who had been HIV-diagnosed during 2000–2009, within ≤6
months before entry into care at a HOPS site (i.e., had a
recentHIVdiagnosis),hadcompleterecordsofantiretroviral
use (if any), and had a CD4 count measured at the time of
HIVdiagnosis(upto3monthsafterHIVdiagnosisdate)and
before having received any antiretroviral treatment. Thus we
focused on subset of patients who entered HOPS care after
a recent (i.e., within the past 6 months) diagnosis of HIV
infection, for whom we had more complete data on CD4
count at HIV diagnosis.
We deﬁned medical coverage/insurance (insurance) as
private for the following payer categories: health mainte-
nance organization, preferred provider organization, point
of service plans, “self-pay/fee-for-service,” and “other private
insurance.” We deﬁned the following payer categories as
public insurance: Medicaid, Medicare, Ryan White/AIDS
Drug Assistance Program, and “public, state funded.” We
deﬁned the categories other, unknown, and “clinical study”
as other or unknown insurance.
We classiﬁed the following HOPS sites, which serve
diverse patient populations, including indigent patients, as
public facilities: State University of New York (SUNY), Stony
Brook, NY; Temple University School of Medicine, Philadel-
phia, PA; University of Illinois at Chicago, Chicago, IL. The
remaining institutions listed in the Acknowledgments were
classiﬁed as private facilities.
2.3. Analysis Methods. We used chi-square or Fisher’s Exact
test to analyze categorical variables and the Wilcoxon rank
sum test to compare distributions of continuous variables.
We examined median CD4 counts and the proportion
of patients having a CD4 count <200cells/mm3 at HIV
diagnosis during the entire period 2000–2009 and by ﬁve
two-year periods within this time frame: 2000-2001, 2002-
2003, 2004-2005, 2006-2007, and 2008-2009. We assessed
temporal trends in the distribution of CD4 counts at HIV
diagnosis using the Jonckheere-Terpstra nonparametric test
and assessed trends in the proportion of persons diagnosed
with CD4 count <200cells/mm3 by calendar period using
the Cochran-Armitage test. Factors associated with having
a CD4 count <200cells/mm3 at HIV diagnosis (also termed
“late HIV diagnosis” henceforth) were examined using
multiple logistic regression. Factors considered in the logistic
models included patient’s age, gender, race/ethnicity, HIV
risk, and patient’s insurance (private versus public or none).
We chose to evaluate patient’s insurance rather than the
type of HOPS site (private versus public facility) in the
primary multivariable model because these two variables
were correlated and because we hypothesized that patient’s
insurance would be more closely tied to behaviors and
circumstances associated with late HIV testing; we evaluated
type of HOPS facility, in place of patient’s insurance, in an
alternate multivariable model.
We also performed additional analyses of trends in CD4
count at diagnosis after transforming data on the square-
root scale. The data describing the location of initial HIV
diagnosis were collected systematically since mid-2005 and
were analyzed only for patients diagnosed in 2006–2009.
Finally, we evaluated the percentage of persons who
developed AIDS(deﬁned asCD4 countof <200cells/mm3 or
CD4+ T-lymphocyte percentage of total lymphocytes of <14
or documentation of an AIDS-deﬁning condition) within 12
months of HIV diagnosis [1].
3. Results
Of 3,670 new HOPS participants seen at 10 HIV clinics
during 2000–2009, 1,223 (33%) had a recent HIV diagnosis
(≤6 months before entry into care at a HOPS site). Com-
pared with the 2,447 patients who were diagnosed with HIV
infection >6 months prior to entry into care at a HOPS site
(and may have been in care elsewhere), recently diagnosed
patients were signiﬁcantly (P<0.05) more likely to be ARV
na¨ ıve(86%versus16%),younger(medianageof38versus40
years), to have heterosexual activity as their sole risk for HIV
infection (37% versus 25%), to be privately insured (61%
versus 51%), less likely to be male (75% versus 80%), lessAIDS Research and Treatment 3
Table 1: Characteristics of patients diagnosed with HIV infection within 6 months before study entry with available CD4 count data∗ by
study period during which HIV diagnosis occurred, the HIV Outpatient Study, 2000–2009.
2000-2001
(n = 213)
2002-2003
(n = 224)
2004-2005
(n = 207)
2006-2007
(n = 145)
2008-2009
(n = 147)
P value for
trend†
All years
(n = 936)
Males, % 75 71 81 81 76 0.21 77
Age, median years (IQR) 37 (30–45) 38 (30–45) 39 (31–46) 36 (28–46) 36 (28–46) 0.50 38 (30–46)
Race/ethnicity,%
Non-Hispanic white 44 39 47 48 36 0.67 43
N o n - H i s p a n i c b l a c k 3 74 43 63 44 4 0 . 8 3 3 9
Hispanic 15 13 14 14 18 0.59 15
O t h e r o r u n k n o w n 43343 0 . 6 5 3
HIV infection risk group,
%
Men who have sex with
men (MSM) 50 48 57 69 49 0.08 54
H i g h - r i s k h e t e r o s e x u a l 3 94 13 22 14 4 0 . 2 6 3 6
Injection drug use
(IDU, including MSM
IDU)
66631 0 . 0 2 5
O t h e r o r u n k n o w n 56567 0 . 5 4 6
Medical insurer,%
Privately insured 57 67 67 70 58 0.51 64
Publically insured 34 29 29 24 33 0.37 30
O t h e r o r u n k n o w n 9436 1 0 0 . 7 0 6
Type of facility,%
Public 28 46 42 28 49 0.03 39
P r i v a t e 7 25 45 87 25 1 0 . 0 3 6 1
∗For inclusion in this analysis, patients must have had a CD4 cell count measured within 1 month prior to or up to 3 months after the date of HIV diagnosis
while remaining antiretroviral-na¨ ıve.
†By Cochran-Armitage test for proportions (%), and by Jonckheere-Terpstra nonparametric test for continuous variables.
likely to be of white race (40% versus 47%), and less likely to
have injection drug use (IDU) activity as their sole risk for
HIV infection (6% versus 11%).
Of the 1,223 patients with recent diagnoses, 936 (77%)
had a CD4 count documented within 3 months following
HIV diagnosis while still antiretroviral na¨ ıve (a median of 15
days, IQR: 4–34 days after diagnosis). Of these 936 patients
(median age = 38, range: 17–77 years), 77% were male,
43% were white, 39% were black, 54% were men who had
sex with men (MSM), 36% had heterosexual HIV risk, and
5% were injection drug users (Table 1). The 23% of patients
whom we excluded because they did not have a CD4 count
documented in the relevant timeframe were signiﬁcantly
more likely to have had a history of IDU (9% versus 5%), to
have public insurance (41% versus 29%), and to have been
antiretroviral-experienced (23% versus 7%) at entry into
care at a HOPS site.
3.1. Trends in CD4 Counts at HIV Diagnosis. The overall
median CD4 count at HIV diagnosis was 299cells/mm3
(mean = 339, IQR 100–498); among patients diagnosed in
2000-2001 and 2008-2009 the median CD4 counts were
284cells/mm3 and 314cells/mm3,r e s p e c t i v e l y ,( P value for
trend across the ﬁve two-year time periods = 0.13) (Table 2).
We also found no linear trend in CD4 counts at diagnosis
by calendar period after data were transformed on the
square-root scale to normalize the distributions and were
analyzed by generalized linear models (data not shown).
Although not statistically signiﬁcant, there was a trend
towardimprovementinCD4cellcountsamongpatientswho
had heterosexual contact as a risk factor for HIV infection
and those seen in public HOPS clinics (Table 2).
3.2. Low CD4 Counts at HIV Diagnosis. Among the 936
recently diagnosed patients who had CD4 cell count data
available, 337 (36%) were diagnosed with a CD4 count
<200cells/mm3 (i.e., had a late HIV diagnosis), 39% of
patients diagnosed in 2000-2001 and 35% of patients
diagnosed in 2008-2009 (Cochran-Armitage test for trend
across the ﬁve two-year periods, P = 0.21) (Figure 1).
During 2000–2009, late HIV diagnoses were signiﬁcantly
(P<0.05) more common among black (42%) and Hispanic
(46%) patients compared with white patients (28%), among
patients with public (42%) versus private insurance (34%),
and among patients entering care at public versus private
HOPS clinics (45% versus 30%, resp.). The frequency of late
HIV diagnoses was signiﬁcantly lower among MSM (27%)
compared with all other risk groups (47%).4 AIDS Research and Treatment
Table 2: Median CD4 cell count (cells/mm3) at HIV diagnosis∗ by demographic characteristics and study period during which HIV
diagnosis occurred, the HIV Outpatient Study, 2000–2009. Table presents only strata including at least 100 patients in the study.
2000-2001
(n = 213)
2002-2003
(n = 224)
2004-2005
(n = 207)
2006-2007
(n = 145)
2008-2009
(n = 147)
P value for
trend†
All years
(n = 936)
Overall, median
(interquartile range) 284 (99–438) 298 (71–523) 288 (110–501) 320 (139–517) 314 (90–502) 0.13 299 (100–498)
Overall, mean (95%
conﬁdence interval) 312 (277–347) 346 (306–386) 341 (302–380) 354 (312–396) 353 (303–402) — 339 (321–358)
By gender
Male (n = 716) 272 320 293 355 305 0.34 304
Female (n = 220) 287 258 283 222 374 0.22 286
By race/ethnicity
Non-Hispanic white
(n = 400) 362 333 316 383 352 0.69 348
Non-Hispanic black
(n = 365) 243 272 282 264 276 0.60 271
By HIV infection risk
group
MSM (n = 505) 351 375 308 386 336 0.80 351
Heterosexual (n = 372) 209 247 229 288 293 0.09 247
By medical insurer
Privately insured
(n = 596) 284 336 301 343 328 0.38 310
Publicly insured
(n = 283) 230 267 234 213 294 0.27 260
By type of facility
Public (n = 361) 208 225 277 212 276 0.10 247
Private (n = 575) 331 337 310 343 352 0.32 330
∗For inclusion in this analysis, patients must have had a CD4 cell count measured within 1 month prior to or up to 3 months after the date of HIV diagnosis
while remaining antiretroviral-na¨ ıve.
†By Jonckheere-Terpstra nonparametric test for continuous variables.
‡DiﬀerencesinCD4countsbyrace/ethnicity,HIVinfectionriskgroup,insurance,andtypeoffacilitywereallstatisticallysigniﬁcant(nonparametricW ilco x on
rank sum test P<0.05).
Five hundred forty-one (58%) patients were HIV-
diagnosed with a CD4 count <350cells/mm3, 61% of
patients diagnosed in 2000-2001 and 56% of patients
diagnosed in 2008-2009 (Cochran-Armitage test for trend
across the ﬁve two-year time periods, P = 0.29). The
percentages of HIV diagnoses made among persons with
a CD4 count <350cells/mm3 were also signiﬁcantly higher
for blacks (63%) and Hispanics (65%) compared with
whites (50%), for patients with public (63%) versus private
(55%) insurance, and for patients entering care at public
versus private HOPS clinics (66% versus 53%, resp.). The
frequency of HIV diagnoses made with an initial CD4 count
<350cells/mm3 was lower among MSM (50%) compared
with all other risk groups (67%). Only about 25% of patients
were HIV-diagnosed with CD4 cell counts ≥500cells/mm3,
and could potentially beneﬁt from early antiretroviral treat-
ment initiation per the latest US guidelines [21].
Univariate analyses of factors associated with an HIV
diagnosis at a CD4 count <200cells/mm3 did not reveal
substantive diﬀerences in associated predictors across the
ﬁve two-year analysis periods(data not shown). In uni-
variate logistic regression analyses for all patients (n =
936), factors associated with late HIV diagnosis included
white race/ethnicity (odds ratio OR=0.53, 95% conﬁdence
interval CI: 0.40–0.70); age <35 years old (OR=0.45, 95%
CI: 0.32–0.64 versus age 35–42 years old); having as a
risk for HIV infection not being MSM, or in other words,
having high-risk heterosexual, IDU, or another risk (e.g.,
hemophilia, blood transfusion or occupational exposure)
(OR=2.49, 95% CI: 1.90–3.28 versus MSM), and having
publicinsuranceatentryintocareataHOPSsite(OR=1.43,
95% CI: 1.07–1.93 versus private insurance).
Inmultivariablelogisticregressionanalyses,independent
correlates of HIV diagnosis with CD4 count <200cells/mm3
were having as a risk for HIV infection not being MSM
(OR=1.99, 95% CI 1.45–2.72), age ≥35 years at diagnosis
(OR=2.14, 95% CI 1.59–2.87), and being of nonwhite race
(OR=1.45, 95% CI 1.05-2.01). The association between
late HIV diagnosis and having public insurance that was
observed in the univariate analyses did not persist in the
adjustedanalyses.Inanalternatemultivariablemodel,which
included type of HOPS site (public versus private facility)AIDS Research and Treatment 5
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Figure 1: CD4 cell count (cells/mm3) by period of HIV diagnosis,
the HIV Outpatient Study 2000–2009 (N = 936).
instead of patient’s insurance, the type of HOPS site was also
not associated with late HIV diagnosis after controlling for
patient’s age, race/ethnicity, and HIV risk group.
3.3.AIDSwithin1YearofHIVDiagnosis. Becausedocumen-
tation of AIDS opportunistic illnesses may be incomplete at
thetimeofinitialHIVdiagnosis,weevaluatedthepercentage
of persons who developed AIDS (by immunologic or clinical
criteria) ≤12 months of HIV diagnosis. Across the ﬁve two-
yearperiods,respectively,thatpercentagerangedfrom50.2%
for patients diagnosed in 2000-2001 to 50.3% for patients
diagnosed in 2008-2009 (test for trend P = 0.66).
3.4. Circumstances of the Initial HIV Diagnosis. Data on
the venue of initial HIV diagnosis were available for 246
of 292 patients diagnosed in 2006–2009. The predominant
situations in which HIV diagnoses were made included
screening at a routine provider visit (n = 75, 30%), testing
during inpatient hospitalization (n = 43, 17%), testing
at a symptom-driven visit (n = 29, 12%), and testing
at a sexually transmitted disease clinic (n = 25, 10%);
the circumstances surrounding initial HIV diagnosis were
recorded as “unknown” for 29 (12%) of participants.
4. Discussion
Among HOPS patients recently diagnosed with HIV infec-
tion, we found no statistically signiﬁcant improvement in
the median CD4 count at diagnosis during 2000–2009.
Overall, 36% of patients were diagnosed with a CD4 count
<200cells/mm3 and 58% with a CD4 count <350cells/mm3.
Persons whose risk for HIV infection was other than being
MSM, persons aged ≥35 years, and persons of nonwhite
race/ethnicity were more likely to be diagnosed with a CD4
count <200cells/mm3 a n dt h u sm o r el i k e l yt oh a v em i s s e d
an opportunity for timely access to HIV care and initiation
of ARV therapy; the correlates of HIV diagnosis with CD4
<350cells/mm3 were largely similar. Our ﬁnding that MSM
were less likely to be diagnosed with advanced HIV infection
than some other risk groups (e.g., IDUs) is consistent with
the ﬁndings from US HIV surveillance [1, 2] and data from
other HIV cohorts reporting on late HIV diagnosis [23]a n d
presentation for care [15]. The association of younger age
(<35 years) with a lower likelihood of late HIV diagnosis
maybepartiallyexplainedbythefactthatyoungerpersonsde
facto have had less lifetime opportunity, if they became HIV-
infected, to progress to CD4 <200cells/mm3; older age has
been associated with late HIV diagnosis previously [2, 15].
In a recent study by Althoﬀ and colleagues of 44,491
HIV-infected patients enrolled in the North American-
AIDS Cohort Collaboration on Research and Design (NA-
ACCORD), the median CD4 count at ﬁrst presentation to
HIV care increased from 256cells/mm3 (interquartile range,
96–455cells/mm3) to 317cells/mm3 (interquartile range,
135–517cells/mm3) from 1997 to 2007 (P<0.01). The
median CD4 count at HIV diagnosis for HOPS patients
whom we studied (who all entered care within 6 months
of diagnosis, per inclusion criteria) was remarkably similar
to median CD4 count at ﬁrst presentation to HIV care
among NA-ACCORD participants. Our ﬁndings of a high
(approximately 34%) prevalence of late HIV diagnosis
during the period 2004–2007 correspond well with the
estimate from national HIV surveillance (34%) for 2005–
2007, and the national surveillance system also detected no
marked increases in CD4 counts at diagnosis over time [1].
The reason why the median CD4 counts in the HOPS and
NA-ACCORD population were higher as compared with
those in HIV surveillance may be related to several factors.
First, compared with the nationwide HIV epidemic, the
HOPS is enriched in whites and MSM, populations who
tend to be diagnosed at higher CD4 cell counts. Second,
HIVtestingcapacityandthereforetheopportunityfortimely
diagnosis vary by jurisdiction. HOPS clinics are located in
major urban centers with large HIV epidemics where testing
opportunitiesmightbegreaterleadingtoagreaterlikelihood
of indentifying infected persons earlier in the course of their
disease. Third, the CD4 count ﬁndings from national HIV
surveillance are derived from 37 states, some of only report
CD4 counts <200cells/mm3 for HIV-infected persons, a
practice that would tend to bias the median CD4 cell count
downwards [2].
Our results should be interpreted in light of some
additionalimportantcaveats.First,werestrictedouranalyses
to patients diagnosed with HIV within 6 months prior to
entry into care at a HOPS site. We used this criterion because
HOPS patients who initiated HIV care earlier elsewhere
often lack documentation of their initial CD4 count value.
The timeframe of ≤6 months between HIV diagnosis and
entry into care at a HOPS site, however, appeared to capture
well the patients who newly entered care (only 7% of these
patients had any previous ARV exposure). Although we
have thus excluded a subset of patients who delay entry into
HIV care (who may also be more likely to be diagnosed
late in HIV infection) a recent meta-analysis suggests that
approximately 72% of patients enter care within 4 months of
HIV diagnosis [24]. Second, we studied a self-selected group
of recently diagnosed patients who, by deﬁnition, entered
HIV care and were also willing to consent to enrollment
in the HOPS; these patients could potentially diﬀer from6 AIDS Research and Treatment
patients not entering care [25, 26]. Available resources
constrain some HOPS sites from enrolling the entire clinic
population, and although attempts are made to balance the
representativeness of the enrollees there is some opportunity
for convenience sampling bias. Additionally, the HOPS does
not enroll patients who present to a HOPS clinic for care but
die prior to the opportunity to consent for the study. Both
of these eﬀects are greater at public facilities compared with
private facilities. Consequently, there might be a tendency
for the HOPS to enroll healthier patients, and, therefore, our
ﬁndings would not represent the entire clinic population
served by HOPS sites or be generalizable to all patients
in cities where HOPS sites are located. Third, the 23% of
patients with recent HIV diagnoses who were excluded
due to missing CD4 count data were more likely to be
IDU and publically-insured, subgroups that tended to have
lower CD4 counts at diagnosis. Therefore our ﬁnding that
approximately one-third of patients were diagnosed with
HIV infection at a CD4 count <200cells/mm3 might be an
underestimate due to this information bias. Finally, because
of small sample sizes in some sociodemographic subgroups
(e.g., Hispanics, high-risk heterosexuals, persons with a
history of IDU) we could not accurately estimate median
CD4 counts and proportions of patients with CD4 counts
<200 at diagnosis by calendar period for these subgroups;
furthermore, estimates for some groups (e.g., women) could
be subject to considerable random variability over time.
The CDC recommendations for universal opt-out HIV
testing were published in September 2006; in light of
inherent reporting delays with HIV surveillance data and
data incompleteness, the evidence as to whether these
guidelines have led to earlier HIV diagnosis (i.e., at higher
CD4 counts) nationwide is not likely to be apparent for
some time. Nonetheless, encouraging trends have been seen
in jurisdictions that have dramatically expanded HIV testing
[19, 20]. In our study, we did not detect a statistically
signiﬁcant trend to higher CD4 cell counts at HIV diagnosis
overall, although the pattern of change was in the direction
of increasing CD4 cell counts, particularly for patients with
heterosexual exposure as a risk factor for HIV infection and
those presenting to public facilities.
In conclusion we have found that even among HOPS
participants who successfully entered care, over one-third
were diagnosed with CD4 counts <200cells/mm3 and over
one-half were diagnosed with CD4 count <350cells/mm3,
the threshold at which initiating cART is unequivocally
recommended (up to CD4 count of 500cells/mm3,a b o v e
which level it is to be considered) [21]. These ﬁndings
should raise concern. Prompt HIV diagnosis, entry into care,
and timely initiation of cART are critical for reducing the
risk of both opportunistic and nonopportunistic disease,
prolonging survival, and reducing onward HIV transmis-
sion. Our ﬁndings also suggest that expanding testing and
reducing late HIV diagnosis need to be a priority, if the
programs related to improving linkage to care and earlier
antiretroviral treatment initiation [22] are to reach patients
and potentially alter the trajectory of the US HIV epidemic
[27]. An estimated 21 to 25% of HIV-infected persons in
the USA remain undiagnosed [9, 10], with the prevalence of
unrecognized HIV infection approaching 50% among some
urban MSM [28]. Many untested persons either perceive
themselves to be at low risk of HIV infection or are fearful
of learning their HIV status [28]. Such persons are more
likely to have a late stage or illness-triggered diagnosis. Our
ﬁndingsreinforcetheneedtoestablishuniversalroutineHIV
testing as standard of care for all adolescents and adults seen
in private and public care settings, regardless of patient-
r e p o r t e dH I Vr i s k[ 11]. It is only under such circumstances
that late-stage or illness-triggered HIV diagnoses will be
reduced and that sociodemographic disparities in stage of
HIV disease at diagnosis be eliminated.
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